海南医学院附属医院/海南省人民医院
Hainan General Hospital / Hainan Medical University hospitals
在本站收录的 53 种疾病中,这家医院列在其中 18 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
海南医学院附属医院/海南省人民医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma25 篇牵头论文牵头 1 项开放试验
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma51 篇牵头论文
- 胃癌Stomach cancer29 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
- 骨肉瘤Osteosarcoma4 篇牵头论文
- 神经母细胞瘤Neuroblastoma1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma2 篇牵头论文
- 再生障碍性贫血Aplastic anaemia2 篇牵头论文
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
- β 地中海贫血Beta thalassaemia6 篇牵头论文
- 范可尼贫血Fanconi anaemia1 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder5 篇牵头论文
- 重症肌无力Myasthenia gravis0 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis0 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis5 篇牵头论文
- IgA 肾病IgA nephropathy2 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文
未列出的收录疾病:肝母细胞瘤、脊索瘤、胃肠道间质瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 1.1%。
海口有 2 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
- 分期
- 不分期
- 开始
- 2026-02
- 登记号
- NCT06796270
年龄 18 岁 至 75 岁(登记的条件)
牵头:海南医学院附属医院/海南省人民医院海口
- 正在招募Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
- 分期
- II期
- 开始
- 2025-02
- 登记号
- NCT06811844
年龄 18 岁 至 65 岁(登记的条件)
牵头:厦门大学附属第一医院;另有 1 家列出的医院为研究中心厦门、海口
- 正在招募A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
- 分期
- I/II期
- 开始
- 2025-11
- 登记号
- NCT07258979
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、东莞、南宁、南昌、厦门、广州、成都、昆明、杭州、桂林、江门、海口、福州、重庆、长沙、韶关
- 正在招募Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- 分期
- III期
- 开始
- 2024-03
- 登记号
- NCT06239727
年龄 18 岁 至 65 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙
- 正在招募Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- 分期
- 不分期
- 开始
- 2023-06
- 登记号
- NCT05892354
年龄 18 岁 至 70 岁(登记的条件)
牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文25
- Interpretable multimodal MRI radiomics for predicting neoadjuvant chemotherapy response in nasopharyngeal carcinoma.
- Dynamic contrast-enhanced magnetic resonance imaging-based radiomics for predicting programmed death ligand 1 expression in nasopharyngeal carcinoma.
- Predicting progression-free survival using dynamic contrast-enhanced imaging-based radiomics in advanced nasopharyngeal carcinoma patients treated with nimotuzumab.
- ALYREF stabilizes CREPT mRNA to accelerate the development of nasopharyngeal carcinoma through dependence on m5C modification.
- The SOX1:c.1036A > G:p.M346V variant act as an pathogenic gene in nasopharyngeal carcinoma.
- Targeted Nanoparticle-Based Therapies for Nasopharyngeal Carcinoma: Enhancing Radiosensitization, Photothermal Therapy, and Diagnostics.
- Effect of MicroRNA-4713-3p on Promoting Malignant Progression of Nasopharyngeal Carcinoma via Targeted Inhibition of EPHX3 to Activate Wnt/β-Catenin Signaling Pathway.
- High α-lipoic acid-loaded hollow mesoporous prussian blue nanozymes for targeted therapy of nasopharyngeal carcinoma in mice.
- miR-144-3p Regulates the Radiation Sensitivity of Nasopharyngeal Carcinoma Through Targeting the NFE2L2 Pathway.
- Dynamic monitoring of radiation-induced white matter microstructure injury in nasopharyngeal carcinoma via high-angular resolution diffusion imaging.
- Effect of blood oxidative stress indicators on oral mucositis in patients undergoing radiotherapy for nasopharyngeal carcinoma.
- Nomograms based on multiparametric MRI radiomics integrated with clinical-radiological features for predicting the response to induction chemotherapy in nasopharyngeal carcinoma.
- Single-cell sequencing analysis reveals the dynamic tumour ecosystems of primary and metastatic lymph nodes in nasopharyngeal carcinoma.
- Effects and mechanisms of prussian blue nanozymes with multiple enzyme activities on nasopharyngeal carcinoma cells.
- Low Expression of BIRC5-206 Promotes Cancer Progression in Nasopharyngeal Carcinoma via Enhancing Expression of Stem Cell Markers.
- Survival rate prediction of nasopharyngeal carcinoma patients based on MRI and gene expression using a deep neural network.
- Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era.
- Multifunctional Nanotheranostics for Dual-Modal Imaging-Guided Precision Therapy of Nasopharyngeal Carcinoma.
- Causes of Death in Long-Term Nasopharyngeal Carcinoma Survivors.
- Drug-Loaded Acoustic Nanodroplet for Dual-Imaging Guided Highly Efficient Chemotherapy Against Nasopharyngeal Carcinoma.
- Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patients.
- Regenerating gene IA predicts radiosensitivity and survival in nasopharyngeal carcinoma.
- Biopsy of cervical lymph node does not impact the survival of nasopharyngeal carcinoma.
- Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma: A pilot study.
- DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1α, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients.
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
- Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma
- A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
- Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
- To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
- Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
- Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma
PubMed 以外找到的论文(未计入)6
- Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)
- Efficacy and safety of serplulimab with DP induction chemotherapy followed by nimotuzumab and IMRT in locally advanced nasopharyngeal carcinoma: A retrospective study.
- Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.
- GSH‐Responsive Shape‐Transformable Nanotheranostics for Dual‐Modal T 1 /T 2 MRI‐Guided Enhanced PDT of Nasopharyngeal Carcinoma
- MYL2 is a potential diagnostic, prognostic, and immune biomarker for HNSC
- 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 1 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文4
- Research Progress on Neoadjuvant Immunotherapy in Esophageal Squamous Cell Carcinoma.
- USP8-Dependent Family Tyrosine Kinase Promotes the Malignant Progression of Esophageal Squamous Cell Carcinoma by Upregulating Protein Tyrosine Kinase 2 Expression.
- MicroRNA-196a-5p facilitates the onset and progression via targeting ITM2B in esophageal squamous cell carcinoma.
- Analysis of clinical efficacy and prognostic side effects of radiotherapy with Teggio capsule on 78 elderly patients with esophageal cancer.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 51 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
海口有 1 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- 分期
- I期
- 开始
- 2025-11
- 登记号
- NCT07176650
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春
- 正在招募Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- 分期
- III期
- 开始
- 2023-05
- 登记号
- NCT05862337
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙
- 即将招募A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
- 分期
- 未注明
- 开始
- 2025-10
- 登记号
- NCT07156617
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心南昌、海口、郑州
- 即将招募The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib:A Prospective, Single-arm, Multicenter, Observational Study
- 分期
- 未注明
- 开始
- 2025-10
- 登记号
- NCT07180459
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心海口
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文51
- Elevated expression of CK19, Ki67, and β-Catenin as prognostic biomarkers in hepatocellular carcinoma.
- Arsenic sulfide alleviates the progression of liver cancer malignancy by inhibiting the expression of TLCD1 in mice.
- Programmed cell death protein 5 inhibits hepatocellular carcinoma progression by inducing pyroptosis through regulation of TGF-β/Smad2/3/Snail pathway.
- Tumor exosomal RNPEP promotes lung metastasis of liver cancer via inducing cancer-associated fibroblast activation.
- Targeting B4GALT3 in BMSCs-EVs for Therapeutic Control of HCC via NF-κB pathway inhibition.
- Cinobufacini Inhibits Survival and Metastasis of Hepatocellular Carcinoma via c-Met Signaling Pathway.
- Role of the Wnt/β-catenin signaling pathway in the development of HCC.
- Dual function of Gasdermin E: pyroptosis-mediated pan-cancer suppression versus HCC-specific oncogenic activity.
- Mechanistic insights into FUNDC2P4 and HSF1 regulation of EMT in residual hepatocellular carcinoma following insufficient radiofrequency ablation.
- HBx Drives Liver Cancer Stem Cell Generation Through Stimulating Glucose Metabolic Reprogramming.
- DPHC from Alpinia officinarum Hance specifically modulates the function of CENPU in the cell cycle and apoptosis to ameliorate hepatocellular carcinoma.
- A versatile nanoplatform for enhanced sonodynamic therapy via hypoxia alleviation, glutathione depletion, and calcium overload.
- Integrative genomics characterizes HCC eRNAs for prognosis and targeted therapy.
- STAT3-mediated upregulation of TRIM6 promotes hepatocellular carcinoma invasion through the DDX58-Snail1 axis.
- IL-6/STAT3 signaling pathway induces prostate apoptosis response protein-4(PAR-4) to stimulate malignant behaviors of hepatocellular carcinoma cells.
- CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells.
- Integrating network pharmacology, bioinformatics, and experimental validation to unveil the molecular targets and mechanisms of galangin for treating hepatocellular carcinoma.
- Dendrobium nobile active ingredient Dendrobin A against hepatocellular carcinoma via inhibiting nuclear factor kappa-B signaling.
- Conversion therapy for initially unresectable hepatocellular carcinoma: Current status and prospects.
- Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis.
- Prognostic value and gene regulatory network of CMSS1 in hepatocellular carcinoma.
- Ropivacaine synergizes with sorafenib to induce apoptosis of hepatocellular carcinoma cells via the IL-6/STAT3 pathway.
- Long noncoding RNA SNHG3 interacts with microRNA-502-3p to mediate ITGA6 expression in liver hepatocellular carcinoma.
- Ropivacaine combined with sorafenib attenuates hepatocellular carcinoma cell proliferation and metastasis by inhibiting the miR-224/HOXD10 axis.
- β-Sitosterol suppresses hepatocellular carcinoma growth and metastasis via FOXM1-regulated Wnt/β-catenin pathway.
- Kaempferol from Alpinia officinarum hance induces G2/M cell cycle arrest in hepatocellular carcinoma cells by regulating the ATM/CHEK2/KNL1 pathway.
- Exploring the role of CDCA4 in liver hepatocellular carcinoma using bioinformatics analysis and experiments.
- Hypoxia-driven lncRNA CTD-2510F5.4: a potential player in hepatocellular carcinoma's prognostic stratification, cellular behavior, tumor microenvironment, and therapeutic response.
- A Novel RNA Methylation-Related Prognostic Signature and its Tumor Microenvironment Characterization in Hepatocellular Carcinoma.
- Prior to ABOi liver transplant with PD-1 inhibitor in patients with hepatocellular carcinoma: A case report.
- Knockdown of LPCAT1 Repressed Hepatocellular Carcinoma Growth and Invasion by Targeting S100A11.
- Integrating Network Pharmacology and Bioinformatics to Explore the Effects of Dangshen (Codonopsis pilosula) Against Hepatocellular Carcinoma: Validation Based on the Active Compound Luteolin.
- β-Sitosterol activates autophagy to inhibit the development of hepatocellular carcinoma by regulating the complement C5a receptor 1/alpha fetoprotein axis.
- Alpha fetoprotein promotes polarization of macrophages towards M2-like phenotype and inhibits macrophages to phagocytize hepatoma cells.
- Secukinumab plays a synergistic role with starvation therapy in promoting autophagic cell death of hepatocellular carcinoma via inhibiting IL-17A-increased BCL2 level.
- Components of the JNK-MAPK pathway play distinct roles in hepatocellular carcinoma.
- Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study.
- Efficacy of sequential TACE on primary hepatocellular carcinoma with microvascular invasion after radical resection: a systematic review and meta-analysis.
- Contribution of PNPLA3 gene polymorphisms to hepatocellular carcinoma susceptibility in the Chinese Han population.
- Circular RNA Circ-STIL Contributes to Cell Growth and Metastasis in Hepatocellular Carcinoma via Regulating miR-345-5p/AQP3 Axis.
- α-Fetoprotein fragment synergizes with sorafenib to inhibit hepatoma cell growth and migration and promote the apoptosis.
- Long noncoding RNA LINC01132 enhances immunosuppression and therapy resistance via NRF1/DPP4 axis in hepatocellular carcinoma.
- Involvement of CDK11B-mediated SPDEF ubiquitination and SPDEF-mediated microRNA-448 activation in the oncogenicity and self-renewal of hepatocellular carcinoma stem cells.
- ECT2 overexpression promotes the polarization of tumor-associated macrophages in hepatocellular carcinoma via the ECT2/PLK1/PTEN pathway.
- Diagnostic performance of intravascular perfusion based contrast-enhanced ultrasound LI-RADS in the evaluation of hepatocellular carcinoma.
- Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance.
- Long noncoding RNA NBAT1 suppresses hepatocellular carcinoma progression via competitively associating with IGF2BP1 and decreasing c-Myc expression.
- Expression changes of miRNA-203 before and after transcatheter arterial chemoembolization in hepatocellular carcinoma patients and its clinical significance.
- Association between SOCS3 hypermethylation and HBV-related hepatocellular carcinoma and effect of sex and age: A meta-analysis.
- Identification of an 11-lncRNA signature with high performance for predicting the prognosis of hepatocellular carcinoma using bioinformatics analysis.
- MTIF2 impairs 5 fluorouracil-mediated immunogenic cell death in hepatocellular carcinoma in vivo: Molecular mechanisms and therapeutic significance.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib:A Prospective, Single-arm, Multicenter, Observational Study
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 29 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
海口有 1 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07385703
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- 分期
- 未注明
- 开始
- 2025-02
- 登记号
- NCT06846996
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文29
- Association between preoperative high-density lipoprotein cholesterol levels and overall survival in gastric cancer patients: a retrospective cohort study.
- Construction of a Prognostic Model for Lysosome-dependent Cell Death in Gastric Cancer Based on Single-cell RNA-seq and Bulk RNA-seq Data.
- Artificial intelligence system improves the quality of digestive endoscopy: A prospective pretest and post-test single-center clinical trial.
- Case Report: Pathological complete response achieved with neoadjuvant immunochemotherapy in synchronous multiple gastric adenocarcinoma.
- Development and validation of an ARID1A-related immune genes risk model in evaluating prognosis and immune therapeutic efficacy for gastric cancer patients: a translational study.
- Network pharmacology, molecular docking, and molecular dynamics simulation analysis reveal the molecular mechanism of halociline against gastric cancer.
- Dendrobin A inhibits gastric cancer: Mechanistic insights supported by integrated evidence.
- Bibliometric-based visualization of endoscopic treatment of early gastric cancer.
- Regulation of cagA-Helicobacter on gastric PIM2 expression in gastric cancer.
- Efficacy and Safety of Low-Dose Apatinib Combined with Chemotherapy as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis.
- Influence of cancer-directed surgery on the prognosis of liver metastases from gastric cancer.
- Prognostic value of RNA methylation-related genes in gastric adenocarcinoma based on bioinformatics.
- Comment on: Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).
- Risk model and factors for prediction of response to neoadjuvant chemotherapy in patients with advanced gastric cancer-a two-center cohort study.
- A survey on Helicobacter pylori infection rate in Hainan Province and analysis of related risk factors.
- Prenatal diagnosis of hereditary diffuse gastric cancer: a case report.
- An Unusual Cause of Gastric Masses.
- ASF1B acted as a prognostic biomarker for stomach adenocarcinoma.
- Application effect of gastrointestinal bundle nursing on the protection of gastrointestinal function in patients with gastric cancer.
- Low SP1 SUMOylation-dependent SNHG17 upregulation promotes drug resistance of gastric cancer through impairing hsa-miR-23b-3p-induced Notch2 inhibition.
- Circ_0075825 promotes gastric cancer progression via adsorbing miR-432-5p to modulate SOX9.
- Efficacy of Traditional Chinese Medicine Combined with Chemotherapy in the Treatment of Gastric Cancer: A Meta-analysis.
- HuR confers IL-17a-induced migration and invasion of gastric cancer cells via upregulation of Snail translation.
- A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract.
- Differential Expression of α-Enolase in Clinical Gastric Tissues and Cultured Normal/Cancer Cells in Response to Helicobacter pylori Infection and cagA Transfection.
- Ethanol Extract of Eryngium Foetidum Leaves Induces Mitochondrial Associated Apoptosis via ROS Generation in Human Gastric Cancer Cells.
- The circular RNA hsa_circ_000780 as a potential molecular diagnostic target for gastric cancer.
- Centromere protein U (CENPU) promotes gastric cancer cell proliferation and glycolysis by regulating high mobility group box 2 (HMGB2).
- Evaluation of the prognostic value of CBXs in gastric cancer patients.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 1 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
这些数字背后的记录
牵头的论文2
- IGF2BP3-dependent N6-methyladenosine modification of USP49 promotes carboplatin resistance in retinoblastoma by enhancing autophagy via regulating the stabilization of SIRT1.
- The long noncoding RNA MALAT1/microRNA-598-3p axis regulates the proliferation and apoptosis of retinoblastoma cells through the PI3K/AKT pathway.
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 2 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
牵头的论文4
- Sulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2/SLC7A11/GPX4 signaling axis.
- The expression and clinical significance of ARHGAP25 in osteosarcoma based on bioinformatics analysis.
- Long noncoding RNA HCP5 promotes osteosarcoma cell proliferation, invasion, and migration via the miR-29b-3p-LOXL2 axis.
- The value of Angipoietin-2 as a biomarker for the prognosis of osteosarcoma: A protocol for systematic review and meta-analysis.
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 4 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
海口有 2 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2023-10
- 登记号
- NCT06049290
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、苏州、西安、贵阳、郑州、长春、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
血液疾病
再生障碍性贫血
Aplastic anaemia2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 1 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 1 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
海口有 3 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
- 分期
- I期
- 开始
- 2024-12
- 登记号
- NCT06772766
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心南宁、海口
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文6
- Association Between KLF1, BCL11A and HBS1L-MYB Polymorphisms and Phenotypes With β-Thalassemia Patients in Hainan.
- Prevalence and molecular spectrum of thalassemia in infertile population among different ethnic groups in Hainan Province, China.
- Prevalence and genetic analysis of thalassemia in childbearing age population of Hainan, The Free Trade Island in Southern China.
- Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.
- Report of Two Novel Thalassemia Variants, HBB: c.181delG and HBA1: c.121_126delAAGACC, in Chinese Individuals.
- Prevalence and molecular spectrum of α- and β-globin gene mutations in Hainan, China.
中文论文(未计入)3
- [Ethnic differences in genotype distribution of thalassemia between Han and Li populations in southern Hainan].
- [Application value of high-throughput sequencing for the detection of thalassemia in ethnic Li minority areas].
- [Detection of Irregular Antibodies after Blood Transfusion for Children with Thalassemia in Hainan].
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
血液疾病
范可尼贫血
Fanconi anaemia2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 1 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 1 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。
这些数字背后的记录
牵头的论文5
- Clinical applications and diagnostic research of GFAP and NfL in MS and NMOSD: a meta-analysis.
- Mycoplasma pneumoniae infection and concurrent aquaporin-4-positive neuromyelitis optica spectrum disorder: a case report and literature review.
- Abnormal functional connectivity of white-matter networks and gray-white matter functional networks in patients with NMOSD.
- Uhthoff's phenomenon as the initial symptom in neuromyelitis optica spectrum disorders: a case report.
- Clinical analysis of neuromyelitis optica spectrum disease with area postrema syndrome as the initial symptom.
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年没有牵头重症肌无力的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 1 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年没有牵头抗 NMDA 受体脑炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 2 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
海口有 1 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07687459
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Contribution of cuproptosis and immune-related genes to idiopathic pulmonary fibrosis disease.
- Single-cell transcriptomics reveals CD8+ T cell structure and developmental trajectories in idiopathic pulmonary fibrosis.
- Single-cell RNA sequencing reveals special basal cells and fibroblasts in idiopathic pulmonary fibrosis.
- Diagnostic value and safety of medical thoracoscopy under local anesthesia for unexplained diffuse interstitial lung disease: A retrospective study.
- Progranulin and Activin A Concentrations are Elevated in Serum from Patients with Acute Exacerbations of Idiopathic Pulmonary Fibrosis.
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 2 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)4
- 3'UTR SNPs in the LPP gene associated with Immunoglobulin A nephropathy risk in the Chinese Han population.
- 3'UTR variants of TNS3, PHLDB1, NTN4, and GNG2 genes are associated with IgA nephropathy risk in Chinese Han population.
- Genetic Variations rs859, rs4646, and rs372883 in the 3'-Untranslated Regions of Genes Are Associated with a Risk of IgA Nephropathy.
- Complement-C1q TNF-Related Protein 3 Alleviates Mesangial Cell Activation and Inflammatory Response Stimulated by Secretory IgA.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
海口有 1 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
联系这家医院
出示给工作人员或司机的院名卡
海南医学院附属医院/海南省人民医院
Hainan General Hospital / Hainan Medical University hospitals
海口
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Hainan General Hospital; Hainan Medical College; Hainan Medical University; First Affiliated Hospital of Hainan Medical University; Second Affiliated Hospital of Hainan Medical University; Hainan Medical College Cancer Institute; Hainan Affiliated Hospital of Hainan Medical University; First Affiliated Hospital of Hainan Medical College